| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Additional Data from MAPLE-HCM Show Aficamten Significantly Improves Measures of Maximal
and Submaximal Exercise Capacity and Recovery Compared to Metoprolol
96-Week Analyses from FOREST-HCM Support
Long-Term Efficacy and Tolerability of Aficamten in Patients with Non-Obstructive HCM
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ: CYTK) today announced that additional data related to aficamten were presented in a Late Breaking Clinical Research session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025 in Minneapolis, MN. The first presentation was a pre-specified analysis of the effect of aficamten compared to metoprolol on exercise performance in obstructive HCM (oHCM) in MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), and the second was an analysis from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM) on the efficacy and tolerability of long-term treatment of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM), simultaneously published in the Journal of Cardiac Failure.
Posted In: CYTK
